Phase 1b Evaluation of Imvotamab in Patients with Severe Systemic Lupus Erythematosus

The primary objective of this study is to evaluate the safety and tolerability of **Imvotamab** in patients with severe **Systemic Lupus Erythematosus**. This is clinically relevant as it aims to determine the potential of Imvotamab as a therapeutic option for managing this chronic autoimmune disease, which can lead to significant morbidity. The study will assess adverse events and any dose-limiting toxicities associated with the treatment.

The clinical trial involves a total of **12 participants** diagnosed with **Systemic Lupus Erythematosus**. The study population includes both male and female subjects, with an age range that spans from adolescents to adults. Participants were selected to ensure a representative sample of the general population affected by this condition, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective or specific inclusion and exclusion criteria for this study.

The clinical trial is designed to evaluate the safety and efficacy of **Imvotamab** in patients with severe **Systemic Lupus Erythematosus**. This study is a Phase 1b trial, which will be conducted as a randomized, double-blind, and controlled trial. The estimated recruitment start date is January 31, 2024, with an anticipated end date of October 13, 2025. The trial will involve multiple study visits, beginning with an inclusion visit to screen potential participants for eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive either the investigational product or a control, with neither the participants nor the investigators aware of the group assignments to maintain blinding.

Participants will be required to attend regular follow-up visits throughout the study duration to monitor their health status, assess the treatment's effects, and ensure adherence to the study protocol. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and questionnaires to evaluate disease activity and treatment response. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement will vary depending on individual response to treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, non-compliance with study procedures, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the potential benefits and risks associated with Imvotamab in treating severe Systemic Lupus Erythematosus, contributing to the advancement of therapeutic options for this condition.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 31, 2024, with an estimated completion date of October 13, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will focus on evaluating the therapeutic impact of the investigational product, with efficacy outcomes being a critical component of the trial's objectives. The trial will employ validated methodologies to ensure the reliability and accuracy of the efficacy data collected throughout the study period.